Clinical trialNCT06745908RecruitingPhase 3Interventional

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

SponsorImmunityBio, Inc.Enrollment507NSCLC Stage IV

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Highlands Oncology Group
Springdale, Arkansas, United States
Eric Schaefer, MD
Recruiting
Chan Soon-Shiong Institute for Medicine
El Segundo, California, United States
Tara Seery, MD
Recruiting
Memorialcare - Orange Coast Medical Center
Fountain Valley, California, United States
Amol Rao
Recruiting
Opn Healthcare Inc
Glendale, California, United States
Anthony Lam
Recruiting
Opn Healthcare Inc/ Cancer and Blood Specialty Clinic
Los Alamitos, California, United States
Vu Phan
Recruiting
Holy Cross Hospital
Fort Lauderdale, Florida, United States
Georges Azzi, MD
Recruiting
the Oncology Institute of Hope and Innovation
Fort Lauderdale, Florida, United States
Edward S Santos, MD
Recruiting
Moffit Cancer Center
Tampa, Florida, United States
Andreas Saltos, MD
Recruiting
Emory University - Winship Cancer Institute
Atlanta, Georgia, United States
Jennifer Carlisle, MD
Recruiting
Barnes-Jewish Hospital - Siteman Cancer Center (washington University - St. Louis)
St Louis, Missouri, United States
Daniel Morgensztern →
Recruiting
Carolina Oncology Specialists
Hickory, North Carolina, United States
Justin Favaro, MD
Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Kerri McGovern, MD
Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Matthew Mirsky, MD
Recruiting
Medical University of South Carolina
Charleston, South Carolina, United States
Mariam Alexander, MD
Recruiting
Tennessee Oncology
Nashville, Tennessee, United States
Wade Iams, MDD
Recruiting
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee, United States
Shuai Wang, MD
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Alexander Spira, MD
Recruiting
Virginia Commonwealth University
Richmond, Virginia, United States
Jonathan Berkman, MD
Recruiting
Medical Oncology Associates - Summit Cancer Centers
Spokane, Washington, United States
Arvind Chaudhry, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Docetaxel →N-803 →Prior failed checkpoint inhibitor →Tislelizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Oct 2025
Primary completion: 30 Sept 2028
Completion: 31 Jan 2029
Last update posted: 5 May 2026
Registered enrollment: 507
Registry id: NCT06745908

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.